Taken together, these results demonstrate that PTPN2 deficiency promotes the LCK‐dependent activation of CAR T cells and overcomes the immunosuppressive tumour microenvironment to eradicate solid tumours in vivo. This evidence concerns the gene PTPN2 and neoplasm.